BioMedPartners
Description
BioMedPartners is a prominent European venture capital firm based in Basel, Switzerland, specializing in investments within the life sciences sector. Established as one of the leading players in the region, the firm focuses on early- to mid-stage private companies primarily in biotechnology and medical technology across Europe. Their investment philosophy centers on identifying and nurturing innovative companies with strong scientific foundations and significant market potential, aiming to support their growth from preclinical development through clinical trials and commercialization.
The firm manages several funds, demonstrating a consistent commitment to the life sciences industry. For instance, their BioMedInvest V fund successfully closed at CHF 200 million (approximately $220 million USD) in 2022, underscoring their continued capacity to deploy substantial capital into promising ventures. This latest fund follows a series of successful predecessors, collectively raising over CHF 500 million (approximately $550 million USD) since the firm's inception, which highlights their long-standing presence and expertise in the market.
BioMedPartners typically acts as a lead or co-lead investor, providing not only financial capital but also strategic guidance and access to their extensive network of industry experts and scientific advisors. They are known for their active involvement in portfolio companies, helping them navigate complex development pathways, regulatory hurdles, and market entry strategies. Their portfolio spans a diverse range of therapeutic areas and technological platforms, reflecting a broad yet focused approach to innovation in healthcare.
With a track record of successful exits and a robust portfolio of over 60 companies, BioMedPartners has solidified its reputation as a key financial and strategic partner for life sciences entrepreneurs in Europe. Their deep industry knowledge, coupled with a patient capital approach, positions them as a crucial catalyst for the development of groundbreaking medical solutions.
Investor Profile
BioMedPartners has backed more than 84 startups, with 1 new investments in the last 12 months alone. The firm has led 27 rounds, about 32% of its total and boasts 21 exits across its portfolio.
Investment Focus Highlights
- Concentrates on Series A, Series B, Series C rounds (top funding stages).
- Majority of deals are located in Switzerland, Germany, United States.
- Strong thematic focus on Biotechnology, Health Care, Therapeutics.
- Typical check size: $3M – $10M.
Stage Focus
- Series A (38%)
- Series B (33%)
- Series C (17%)
- Series D (4%)
- Series Unknown (4%)
- Series E (2%)
- Post Ipo Equity (1%)
- Seed (1%)
Country Focus
- Switzerland (51%)
- Germany (30%)
- United States (6%)
- Belgium (6%)
- France (5%)
- The Netherlands (2%)
Industry Focus
- Biotechnology
- Health Care
- Therapeutics
- Medical
- Medical Device
- Pharmaceutical
- Health Diagnostics
- Life Science
- Clinical Trials
- Manufacturing
Frequently Asked Questions
Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.
